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The British Society for Paediatric and Adolescent Rheuma-
tology (BSPAR) Biologics Register monitors JIA patients
treated with etanercept +/- methotrexate. We report dura-
tion of etanercept use and reasons for discontinuation,
defined as cessation due to disease control or treatment
failure; not including precautionary or temporary drug
discontinuation for transient adverse events. Kaplan-
Meier survival analysis was conducted with remaining
patients censored at five years follow-up.
Results
From 2004–8, 434 etanercept treated JIA patients were
enrolled; 68% female, 15.7% systemic arthritis, mean age
at starting etanercept 11 years (2–21 years). At initiation
of etanercept, 173 (40%) were also being treated with oral
corticosteroids (the "steroid+" group). In 846 patient
years of follow up, 83/434 patients (19.1%) discontinued
etanercept for recorded reasons, 46 of whom (55%) were
in the steroid+ group (table 1).
Discontinuations were due to treatment inefficacy rather
than treatment intolerance in the steroid+ group (p =
0.01). Of the 5 discontinuations due to infection related
adverse events, 4 were in the steroid+ group. Using 5 year
Kaplan-Meier analysis, 55% of all etanercept treated
patients (95% confidence intervals 44.4% – 65.6%) had
not experienced treatment failure. Discontinuation at 5
years was not associated with initial disease severity by
physicians global assessment, systemic arthritis subtype,
starting etanercept before age 10, disease onset before age
5, concurrent methotrexate use or chronic anterior uveitis.
from 15th Paediatric Rheumatology European Society (PreS) Congress
London, UK. 14–17 September 2008
Published: 15 September 2008
Pediatric Rheumatology 2008, 6(Suppl 1):P88 doi:10.1186/1546-0096-6-S1-P88
<supplement> <title> <p>15<sup>th </sup>Paediatric Rheumatology European Society (PreS) Congress</p> </title> <editor>Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/PDF/1546-0096-6-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.ped-rheum.com/content/6/S1/P88
© 2008 Southwood et al; licensee BioMed Central Ltd. Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Pediatric Rheumatology 2008, 6(Suppl 1):P88 http://www.ped-rheum.com/content/6/S1/P88
Page 2 of 2
(page number not for citation purposes)
Table 1: Reasons for stopping Etanercept
Pt Group Inefficacy Intolerance Non-compliance Disease control
Steroid+ 30 (65.2%) 6 (13%) 6 (13%) 4 (8.7%)
Steroid- 14 (37.8%) 14 (37.8%) 4 (10.8%) 5 (13.5%)
44 20 10 9